Saskatchewan SARS-CoV-2 Seroprevalence Study [SaskCov, study data contributed to the CITF databank]

<b>Background:</b> Increased knowledge on seroprevalence rates of SARS-CoV-2 would allow for more educated public health responses in Saskatchewan and provide information for national seroprevalence estimates. <br>

<b>Aims of the CITF-funded study:</b> This study aimed to determine the seroprevalence of SARS-CoV-2 antibodies from infection or vaccination in Saskatchewan, and to link PCR test results to seroprevalence data where possible. <br>

<b>Methods:</b> This repeat cross-sectional study randomly selected residual serum samples collected for the purpose of routine screening and testing from patients across Saskatchewan. Samples were selected over three five- to nine-month periods and tested at the Saskatchewan Health Authority’s Roy Romanow Provincial Laboratory for IgG antibodies to SARS-CoV-2 trimeric spike & nucleocapsid proteins. Further microneutralization testing was conducted by the Vaccine and Infectious Disease Organization (VIDO) at the University of Saskatchewan on a subset of the samples. Researchers obtained permission to link PCR test results collected from Saskatchewan residents to individual seroprevalence results. <br>

<b>Contributed dataset contents:</b> The datasets include samples collected from more than 22,000 participants with a total of 23,956 samples collected across the three sampling periods: 10,858 between April and December 2020, 12,250 between October 2021 and June 2022, and 848 between November 2022 and March 2023. Two-thirds of participants (66%) have linked Saskatchewan Health Authority PCR data. Variables in the datasets include age, sex, region, SARS-CoV-2 serology, microneutralization (for 676 samples), and PCR testing.